



3

UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:) Art Unit:
)
 Lars LANNFELT)
)
 Appln. No.: 09/899,815)
) Washington, D.C.
 Appln. Filed: July 9, 2001)
)
 U.S. App. No.: 09/899,915)
)
) October 22, 2001
 National Filing Date:)
 (Not Yet Received))
)
 For: PREVENTION AND TREATMENT...) Docket No.:LANNFELT=1A

PRELIMINARY AMENDMENT

Honorable Commissioner for Patents and Trademarks
Washington, D.C. 20231

Sir:

Prior to examination upon the merits and prior to
calculation of the filing fee, please amend the above-
identified application as follows:

IN THE CLAIMS

Cancel Claims 1-7 and 16.

Please rewrite claim 21 in amended form as follows:

21. (Amended) A method according to claim 17, in
combination with compound(s) having therapeutic benefits to AD
patients.

REMARKS


The above amendments to the claims are being made in order to eliminate multiple dependency and for the purpose of reducing the filing fee. Please enter this amendment prior to calculation of the filing fee in this case.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with
Markings to Show Changes Made."

Favorable consideration and allowance are earnestly solicited.

Respectfully submitted,
BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By:


Iver P. Cooper
Registration No. 28,005

IPC:sfg
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
F:\B\Bran\Lannfelt1a\Client\Preliminary Amendment.doc



VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claims 1-7 and 16 have been cancelled.

Claim 21 has been amended as follows:

21. (Amended) A method according to claim 17, 18,
19 or 20, in combination with compound(s) having therapeutic
benefits to AD patients.

050399615 102203